SCYX Scynexis Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SCYX

Price (delayed)

$1.845

Market cap

$69.66M

P/E Ratio

1.32

Dividend/share

N/A

EPS

$1.4

Enterprise value

$50.14M

SCYNEXIS, Inc. is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Its lead candidate, ibrexafungerp (formerly ...

Highlights
Scynexis's debt has plunged by 69% YoY
Scynexis's revenue has increased by 3.1% QoQ
The company's EPS has surged by 195% YoY but it fell by 8% QoQ
Scynexis's quick ratio has increased by 38% YoY but it has decreased by 11% QoQ
The equity has declined by 21% since the previous quarter
Scynexis's gross margin has decreased by 10% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.scynexis.com
Peers: CPRX MRNS CTLT

Key stats

What are the main financial stats of SCYX
Market
Shares outstanding
37.75M
Market cap
$69.66M
Enterprise value
$50.14M
Valuations
Price to earnings (P/E)
1.32
Price to book (P/B)
0.94
Price to sales (P/S)
0.63
EV/EBIT
0.71
EV/EBITDA
0.71
EV/Sales
0.36
Earnings
Revenue
$140.14M
EBIT
$70.31M
EBITDA
$70.89M
Free cash flow
$60.16M
Per share
EPS
$1.4
Free cash flow per share
$1.26
Book value per share
$1.96
Revenue per share
$2.93
TBVPS
$2.68
Balance sheet
Total assets
$128.41M
Total liabilities
$55.45M
Debt
$15.08M
Equity
$72.96M
Working capital
$85.81M
Liquidity
Debt to equity
0.21
Current ratio
6.26
Quick ratio
5.93
Net debt/EBITDA
-0.28
Margins
EBITDA margin
50.6%
Gross margin
88.9%
Net margin
47.8%
Operating margin
51.9%
Efficiency
Return on assets
53.4%
Return on equity
117.6%
Return on invested capital
83.8%
Return on capital employed
62.7%
Return on sales
50.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SCYX stock price

How has the Scynexis stock price performed over time
Intraday
6.65%
1 week
9.17%
1 month
7.89%
1 year
-38.29%
YTD
-17.26%
QTD
25.51%

Financial performance

How have Scynexis's revenue and profit performed over time
Revenue
$140.14M
Gross profit
$124.52M
Operating income
$72.67M
Net income
$67.04M
Gross margin
88.9%
Net margin
47.8%
SCYX's operating income has soared by 185% YoY
Scynexis's net margin has soared by 104% YoY but it has decreased by 10% from the previous quarter
The operating margin has soared by 103% YoY but it has contracted by 3.7% from the previous quarter
Scynexis's gross margin has decreased by 10% QoQ

Growth

What is Scynexis's growth rate over time

Valuation

What is Scynexis stock price valuation
P/E
1.32
P/B
0.94
P/S
0.63
EV/EBIT
0.71
EV/EBITDA
0.71
EV/Sales
0.36
The company's EPS has surged by 195% YoY but it fell by 8% QoQ
SCYX's price to book (P/B) is 83% lower than its 5-year quarterly average of 5.5
The equity has declined by 21% since the previous quarter
The P/S is 100% lower than the 5-year quarterly average of 161.2 and 91% lower than the last 4 quarters average of 7.1
Scynexis's revenue has increased by 3.1% QoQ

Efficiency

How efficient is Scynexis business performance
Scynexis's return on assets has surged by 195% YoY but it has decreased by 15% QoQ
SCYX's return on invested capital has surged by 183% year-on-year but it is down by 14% since the previous quarter
The return on equity has surged by 149% year-on-year but it has declined by 35% since the previous quarter
The company's return on sales has surged by 104% YoY but it fell by 11% QoQ

Dividends

What is SCYX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SCYX.

Financial health

How did Scynexis financials performed over time
The total assets is 132% more than the total liabilities
The total assets has grown by 46% YoY but it has contracted by 14% from the previous quarter
The current ratio has grown by 39% YoY but it has contracted by 18% from the previous quarter
Scynexis's debt is 79% less than its equity
The company's debt to equity has shrunk by 99% YoY but it rose by 31% QoQ
Scynexis's debt has plunged by 69% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.